Investigating the effect of glutamine supplementation on the Rectus Femoris and Vastus Intermedius mascles thinckness in patients undergoing laparoscopic sleeve gastrectomy

Start Date20 Jan 2025

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

IRCT20200929048876N4

/ SuspendedNot ApplicableIIT

Evaluation the effect of glutamine on inflammation and infectious events in patients with mild burns involving under 20% of the body area

Start Date21 Oct 2024

Sponsor / Collaborator

Zanjan University of Medical Sciences

NCT06617182

/ Not yet recruitingPhase 2IIT

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury: a Single-center, Open-label, Randomized Controlled Study

At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.

Start Date30 Sep 2024

Sponsor / Collaborator

Xijing Hospital

100 Clinical Results associated with L-Glutamine

100 Translational Medicine associated with L-Glutamine

100 Patents (Medical) associated with L-Glutamine

6,468

Literatures (Medical) associated with L-Glutamine

01 Sep 2025·Neural Regeneration Research

Targeting harmful effects of non-excitatory amino acids as an alternative therapeutic strategy to reduce ischemic damage

Article

Author: Kirov, Sergei A. ; Carretero, Victoria Jiménez ; Hernández-Campano, Jorge ; Álvarez-Merz, Iris ; Hernández-Guijo, Jesús M.

The involvement of the excitatory amino acids glutamate and aspartate in cerebral ischemia and excitotoxicity is well-documented. Nevertheless, the role of non-excitatory amino acids in brain damage following a stroke or brain trauma remains largely understudied. The release of amino acids by necrotic cells in the ischemic core may contribute to the expansion of the penumbra. Our findings indicated that the reversible loss of field excitatory postsynaptic potentials caused by transient hypoxia became irreversible when exposed to a mixture of just four non-excitatory amino acids (L-alanine, glycine, L-glutamine, and L-serine) at their plasma concentrations. These amino acids induce swelling in the somas of neurons and astrocytes during hypoxia, along with permanent dendritic damage mediated by N-methyl-D-aspartate receptors. Blocking N-methyl-D-aspartate receptors prevented neuronal damage in the presence of these amino acids during hypoxia. It is likely that astroglial swelling caused by the accumulation of these amino acids via the alanine-serine-cysteine transporter 2 exchanger and system N transporters activates volume-regulated anion channels, leading to the release of excitotoxins and subsequent neuronal damage through N-methyl-D-aspartate receptor activation. Thus, previously unrecognized mechanisms involving non-excitatory amino acids may contribute to the progression and expansion of brain injury in neurological emergencies such as stroke and traumatic brain injury. Understanding these pathways could highlight new therapeutic targets to mitigate brain injury.

01 Mar 2025·Journal of Environmental Sciences

Metabolic landscape of human alveolar type II epithelial cells undergoing epithelial-mesenchymal transition induced directly by silica exposure

Article

Author: Sun, Jin ; Huang, Yongshun ; Chen, Baowei ; Li, Yizheng ; Zhao, Na ; Yang, Xubin ; Luan, Tiangang ; Zhang, Ruijia ; Nong, Qiying ; Lin, Li ; Yu, Tiantian

Epithelial-mesenchymal transition (EMT) plays an irreplaceable role in the development of silicosis. However, molecular mechanisms of EMT induced by silica exposure still remain to be addressed. Herein, metabolic profiles of human alveolar type II epithelial cells (A549 cells) exposed directly to silica were characterized using non-targeted metabolomic approaches. A total of 84 differential metabolites (DMs) were identified in silica-treated A549 cells undergoing EMT, which were mainly enriched in metabolisms of amino acids (e.g., glutamate, alanine, aspartate), purine metabolism, glycolysis, etc. The number of DMs identified in the A549 cells obviously increased with the elevated exposure concentration of silica. Remarkably, glutamine catabolism was significantly promoted in the silica-treated A549 cells, and the levels of related metabolites (e.g., succinate) and enzymes (e.g., α-ketoglutarate (α-KG) dehydrogenase) were substantially up-regulated, with a preference to α-KG pathway. Supplementation of glutamine into the cell culture could substantially enhance the expression levels of both EMT-related markers and Snail (zinc finger transcription factor). Our results suggest that the EMT of human alveolar epithelial cells directly induced by silica can be essential to the development of silicosis.

01 Mar 2025·MICROVASCULAR RESEARCH

Cardioprotective effects of l-glutamine in an ischemic rat heart model

Article

Author: Nakadate, Yosuke ; Kawakami, Akiko ; Roque, Patricia ; Sato, Hiroaki ; Schricker, Thomas ; Khoutorsky, Arkady ; Matsukawa, Takashi

INTRODUCTION:

l-glutamine has been shown to have cardioprotective effects in models of ischemia-reperfusion injury. Its potential cardioprotective effects when given before and during early reperfusion, however, have not been studied.

METHODS:

This study hypothesized that l-glutamine administered before and after myocardial ischemia provides better cardioprotection than when administered after ischemia only. Eighteen male rat hearts were exposed to 15 min of ischemia using the Langendorff system and randomly assigned to three groups of six each. Group one received Krebs-Henseleit (KH) buffer over 20 min before ischemia and during 20 min of reperfusion (Control), group two received KH buffer containing 2.5 mmol･L^-1 glutamine during reperfusion (Post-Gln) and group three was given KH buffer containing glutamine before and after the ischemic insult (Pre + Post-Gln). Indicators of hemodynamics such as maximum left ventricular derivative of pressure development (LV dP/dt max) were recorded at 5, 10, 15 and 20 min post-reperfusion. Myocardial levels of O-linked β-N-acetylglucosamine (O-GlcNAc) and heat shock protein 70 (HSP70) were measured by Western blotting technique after 20 min of reperfusion.

RESULTS:

The LV dp/dt max in the Pre + Post-Gln group was significantly elevated as compared to the Post-Gln group after 10 min of reperfusion and was significantly higher than in the control group at all-time points. Myocardial expression of O-GlcNAc was increased in the Pre + Post-Gln group (P < 0.01 vs. control) without showing any differences in HSP70.

CONCLUSION:

In this model of stunned myocardium, pre- and post-ischemic administration of l-glutamine improved cardiac function indicating cardioprotective effects, possibly mediated by O-GlcNAc.

News (Medical) associated with L-Glutamine

25 Oct 2024

·www.prnewswire.com

KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)

SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to AND017 in the treatment of Sickle Cell Disease (SCD). AND017 is being developed to treat various anemia indications associated with diseases including non-dialysis dependent chronic kidney disease (NDD-CKD) and dialysis-dependent chronic kidney disease (DD-CKD). The results for AND017's phase 1 in healthy subjects and phase 2 clinical trials in treatment of anemia in NDD-CKD and anemia in DD-CKD are currently being presented at the annual meeting of American Society of Nephrology (ASN) Kidney Week in San Diego. The preclinical work supporting AND017's ODD in SCD will be presented in future scientific meeting and subsequently published in a scientific journal. Sickle Cell Disease (SCD) is a devasting genetic disease with US patient population around 120,000; SCD disproportionally affects Black and African Americans, comprising more than 98% of patients living with this disease. "The FDA's granting of ODD for AND017 underscores the urgent medical need for new therapies, particularly oral drugs to safely and effectively treat patients with SCD," said Dong Liu, Ph.D., Founder, Chairman, and CEO of Kind Pharmaceutical. "The granting of ODD also demonstrates the innovation capability and the vision of Kind Pharmaceutical." "Hydroxyurea and L-glutamine are the limited FDA-approved oral treatments for SCD, AND017 from Kind Pharmaceutical might not only provide a novel oral treatment with unique mechanism of action, but also an obvious better safety and efficacy profile." said Prof. Gang Huang at UT Health San Antonio, Kathryn Mays Johnson Distinguished Chair in Oncology, who is an expert in studies of hematology and various blood diseases, and involved in the preclinical studies of AND017 in SCD. "I am eager to see how a compound with such unbelievable preclinical safety and efficacy data will translate to real world SCD patients." FDA Orphan Drug Designation (ODD) is granted to a drug or biological product to prevent, diagnose or treat a rare disease or condition that affects fewer than 200,000 people in the United States. ODD qualifies KIND for incentives including tax credit for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after AND017's approval for treatment of Sickle Cell Disease (SCD). About Sickle Cell Disease (SCD) Sickle Cell Disease (SCD) affects around 120,000 patients in US and more than 8,000,000 worldwide. As a genetic disease with a single amino acid mutation in the β-globin of mature adult hemoglobin, the hemoglobin molecules of in the red blood cells (RBCs) of SCD patients are prone to aggregate in the tissue after the dissociation of oxygen molecules, which would cause the RBCs sickling in the blood stream and eventually lead to hemolysis and occlusion of capillaries; therefore the hallmarks of SCD are hemolytic anemia and vaso-occlusive crises (VOCs); and SCD causes multiorgan failure and premature death. About AND017 AND017 is a first-in-class hemoglobin elevating agent (HbEA) that targets multiple stages of the red blood cell (RBC) life cycle and is being developed to treat anemia associated with dialysis-dependent chronic kidney disease (DD-CKD), non-dialysis dependent chronic kidney disease (NDD-CKD), cancer-related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. About Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC") KIND is a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers. The company's mission, "kind to human, humble to science, good to patients", drives its commitment to advancing current science to meet unmet medical need. KIND's lead clinical candidate, AND017, first-in-class hemoglobin elevating agent (HbEA), is being developed for treating anemia of various disorders, including dialysis dependent chronic kidney disease (DD-CKD) associated anemia, non-dialysis dependent (NDD) CKD associated anemia, cancer related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. KIND's second clinical candidate, AND019, an orally available brain penetrant selective estrogen receptor degrader (SERD), is being developed to treat ER+/Her2- breast cancer. KIND is also developing promising disruptive next generation ADC technologies. For details, please visit . Contact: Dong Liu, PhD, Chairman and CEO of Kind Pharmaceutical Email: [email protected] Tel: 650-315 6151 SOURCE KInd Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultOrphan DrugPhase 2

25 Oct 2024

·www.biospace.com

KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)

SAN FRANCISCO , Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical (“Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC”), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to AND017 in the treatment of Sickle Cell Disease (SCD). AND017 is being developed to treat various anemia indications associated with diseases including non-dialysis dependent chronic kidney disease (NDD-CKD) and dialysis-dependent chronic kidney disease (DD-CKD). The results for AND017’s phase 1 in healthy subjects and phase 2 clinical trials in treatment of anemia in NDD-CKD and anemia in DD-CKD are currently being presented at the annual meeting of American Society of Nephrology (ASN) Kidney Week in San Diego . The preclinical work supporting AND017’s ODD in SCD will be presented in future scientific meeting and subsequently published in a scientific journal. Sickle Cell Disease (SCD) is a devasting genetic disease with US patient population around 120,000; SCD disproportionally affects Black and African Americans, comprising more than 98% of patients living with this disease. “The FDA’s granting of ODD for AND017 underscores the urgent medical need for new therapies, particularly oral drugs to safely and effectively treat patients with SCD,” said Dong Liu , Ph.D., Founder, Chairman, and CEO of Kind Pharmaceutical. “The granting of ODD also demonstrates the innovation capability and the vision of Kind Pharmaceutical.” “Hydroxyurea and L-glutamine are the limited FDA-approved oral treatments for SCD, AND017 from Kind Pharmaceutical might not only provide a novel oral treatment with unique mechanism of action, but also an obvious better safety and efficacy profile.” said Prof. Gang Huang at UT Health San Antonio, Kathryn Mays Johnson Distinguished Chair in Oncology, who is an expert in studies of hematology and various blood diseases, and involved in the preclinical studies of AND017 in SCD. “I am eager to see how a compound with such unbelievable preclinical safety and efficacy data will translate to real world SCD patients.” FDA Orphan Drug Designation (ODD) is granted to a drug or biological product to prevent, diagnose or treat a rare disease or condition that affects fewer than 200,000 people in the United States . ODD qualifies KIND for incentives including tax credit for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after AND017’s approval for treatment of Sickle Cell Disease (SCD). About Sickle Cell Disease (SCD) Sickle Cell Disease (SCD) affects around 120,000 patients in US and more than 8,000,000 worldwide. As a genetic disease with a single amino acid mutation in the β-globin of mature adult hemoglobin, the hemoglobin molecules of in the red blood cells (RBCs) of SCD patients are prone to aggregate in the tissue after the dissociation of oxygen molecules, which would cause the RBCs sickling in the blood stream and eventually lead to hemolysis and occlusion of capillaries; therefore the hallmarks of SCD are hemolytic anemia and vaso-occlusive crises (VOCs); and SCD causes multiorgan failure and premature death. About AND017 AND017 is a first-in-class hemoglobin elevating agent (HbEA) that targets multiple stages of the red blood cell (RBC) life cycle and is being developed to treat anemia associated with dialysis-dependent chronic kidney disease (DD-CKD), non-dialysis dependent chronic kidney disease (NDD-CKD), cancer-related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. About Kind Pharmaceutical (“Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC”) KIND is a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers. The company’s mission, “kind to human, humble to science, good to patients”, drives its commitment to advancing current science to meet unmet medical need. KIND’s lead clinical candidate, AND017, first-in-class hemoglobin elevating agent (HbEA), is being developed for treating anemia of various disorders, including dialysis dependent chronic kidney disease (DD-CKD) associated anemia, non-dialysis dependent (NDD) CKD associated anemia, cancer related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. KIND’s second clinical candidate, AND019, an orally available brain penetrant selective estrogen receptor degrader (SERD), is being developed to treat ER+/Her2- breast cancer. KIND is also developing promising disruptive next generation ADC technologies. For details, please visit . Contact: Dong Liu , PhD, Chairman and CEO of Kind Pharmaceutical Email: liudong@kindpharmaceutical.com Tel: 650-315 6151 View original content: SOURCE KInd Pharmaceuticals

Clinical ResultOrphan DrugPhase 2

26 Sep 2024

·www.outsourcing-pharma.com

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

The withdrawal decision was prompted by clinical data indicating that the overall benefit of Oxbryta “no longer outweighs the risk” in its target patient population, the company said in a public release . Specifically, the trials outline an “imbalance” in vaso-occlusive crises and fatal events that the company will assess further. The move to stop clinical trials of the drug will last while Pfizer further reviews the available data and investigates the findings. Sickle cell disease is a genetic blood disorder where patients have a mutation in hemoglobin, a protein found in red blood cells. This leads the protein to clump together, causing cells to have a sickle shape that can block blood vessels and carry less oxygen, leading to acute pain and anemia. Oxbryta, whose generic name is voxelotor, is an oral small molecule drug that was first approved by the US Food and Drug Administration (FDA) for the treatment of sickle cell disease in 2019, with an EU approval granted in 2022. The drug is designed to make hemoglobin better at carrying oxygen and less prone to clumping together, making red blood cells more functional. The treatment was previously developed by the U.S. firm Global Blood Therapeutics before the company was snapped up by Pfizer for $5.4 billion in 2022 , and bagged Pfizer $328 million in revenues in 2023 . The big pharma company has notified regulators about the data and doesn’t expect the event to impact its full-year 2024 financial guidance. Nevertheless, the company’s stock price on the New York Stock Exchange slumped by more than 1% at the news yesterday (Wednesday 25th September). googletag.cmd.push(function () { googletag.display('text-ad1'); }); Emphasizing Pfizer’s focus on patient safety, chief medical officer and head of worldwide medical and safety, Aida Habtezion, said in the company release that the Pfizer’s “primary concern is for patients who suffer from SCD, which remains a very serious and difficult-to-treat disease with limited treatment options. We advise patients to contact their physicians to discuss alternative treatment while we continue to investigate the findings from our review of the data.” The global market for sickle cell disease was worth $2.25 billion in 2022 and is expected to grow by 20.1% per year to $9.84 billion by 2030. The main players in the market have included Pfizer with Oxbryta, Novartis with the antibody Adakveo (crizanlizumab) and Generex Biotechnology’s Emmaus Medical with Endari (L-glutamine). In 2017, Endari became the first branded drug for sickle cell disease in decades when it was greenlit by the U.S. FDA. Another driver for the sickle cell disease market is gene therapy, with the first cell-based gene therapies – Casgevy by Vertex Pharmaceuticals and Lyfgenia by Bluebird Bio – approved by the U.S. FDA in late 2023 .

Drug ApprovalGene Therapy

100 Deals associated with L-Glutamine

External Link

KEGG	Wiki	ATC	Drug Bank
D00015	L-Glutamine	A16AA03	DB00130

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Sickle Cell	US	Emmaus Medical, Inc.	07 Jul 2017
Short Bowel Syndrome	US	Emmaus Medical, Inc.	10 Jun 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Beta-Thalassemia	Phase 3	US	Emmaus Medical, Inc.	01 May 2010
Gastrointestinal Neoplasms	Phase 3	FR	Nestlé SA	01 Oct 2007
Diverticulitis	Phase 2	US	Emmaus Medical, Inc.	31 Oct 2021
Pancreatic Ductal Adenocarcinoma	Phase 1	US	Emmaus Medical, Inc.	13 May 2021
Diverticulosis, Colonic	Phase 1	US	Emmaus Medical, Inc.	19 Jul 2019
Diverticulosis, Esophageal	Phase 1	US	Emmaus Medical, Inc.	19 Jul 2019
Diabetes Mellitus, Type 2	Phase 1	US	Emmaus Medical, Inc.	24 Jun 2019
Sepsis	Preclinical	CN	Third Military Medical University	20 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01952847 (CTgov)	Phase 3	Neoplasms \| Mucositis \| Stomatitis ... View more	77	Questionnaires+Glutamine (Radiation Therapy to Esophagus Patient Group - Glutamine)	ccoxnpmwqw(ptgmozgigb) = sqiithpcao ngyhahdiha (zvsinsqrgi, wcojrhhipk - qctcoqyvuo) View more	-	15 Jun 2022
				Questionnaires (Radiation Therapy to Esophagus Patient Group - Placebo)	ccoxnpmwqw(ptgmozgigb) = esasobtzhu ngyhahdiha (zvsinsqrgi, sdtubhytqc - udycmgxgul) View more
EHA2022	Phase 3	Anemia, Sickle Cell	19	L-glutamine	gzymrwftim(kcbfcareaq) = iwtywmzyov tpgyjdacqb (ogdvkecsjy ) View more	-	12 May 2022
NCT01048905 (CTgov)	Phase 2	Thalassemia \| Associated Pulmonary Arterial Hypertension \| Anemia, Sickle Cell	13	L-Glutamine	arutqwaxlw(hyrykzpsmw) = uzkivuyycx mpsqjelfsq (wnhjrdqvdy, blxjwxcaqm - awksnxymmr) View more	-	10 Jun 2021
NCT01952847 (Pubmed \| Invest New Drugs)	Phase 3	Radiation esophagitis	53	Glutamine	advvhrbnvr(vdyicevluv) = uevzoqjtsr uqpzjzsaob (gaefieczua ) View more	Negative	13 Feb 2021
				Glycine placebo	advvhrbnvr(vdyicevluv) = mdjzefxuum uqpzjzsaob (gaefieczua ) View more
NCT00586209 (CTgov)	Phase 2	Thalassemia \| Anemia, Sickle Cell	15	L-Glutamine (L-glutamine)	gcrvbsijzc(fzcypxxxkk) = awbjahbueq otuqzifhek (gdaakpizuz, ffygdcsnnb - vfdwsabixa) View more	-	02 Feb 2021
				Placebo (Placebo)	gcrvbsijzc(fzcypxxxkk) = cezrcjzpbz otuqzifhek (gdaakpizuz, ykqtlixbon - xjkxcsyiln) View more
NCT00125788 (CTgov)	Phase 2	Thalassemia \| Anemia, Sickle Cell	70	L-glutamine (Investigational Product)	tnuocuyeno(kjlvwuqizw) = qzrgvejkls akyihjppag (bcbwlbphgq, zeguzxhwdi - twchuppyrt) View more	-	29 Jan 2021
				Placebo (Placebo)	tnuocuyeno(kjlvwuqizw) = dpkalbctry akyihjppag (bcbwlbphgq, njqvyfsdtc - eckhtsjgkv) View more
NCT01534663 (GLUTFISH-HF, CTgov)	Phase 2/3	Hydrops Fetalis \| Heart Failure	31	Placebo (Placebo)	ydqoxtekcv(ozszwjekwv) = vkscfcercc gszozrfrqr (iefdqysoyt, locmniapab - ylpzhebzvc) View more	-	22 Dec 2020
				Glutamine (Glutamine/Fishoil)	ydqoxtekcv(ozszwjekwv) = pgegsiyqbo gszozrfrqr (iefdqysoyt, qovwqyxwvg - dvjmhmskbe) View more
NCT01783522 (CTgov)	Phase 2	Drug intoxication \| Multiple Myeloma \| Peripheral Nervous System Diseases	9	quality-of-life assessment+glutamine (Arm I (Preventative Nutritional Supplementation))	bsogpyksoi(hyxvvnauyj) = tvfagzbmgi hcyxjtrchr (desfonwntr, uhfcllrxgz - usvlqcjnvn) View more	-	22 Oct 2019
				placebo (Arm II (Placebo))	bsogpyksoi(hyxvvnauyj) = giumozrjzf hcyxjtrchr (desfonwntr, cxpsskfrpe - rdrwtedcve) View more
NCT02012608 (CTgov)	Phase 2	Breast Cancer	14	Glutamine (Glutamine)	mlntsourwi(inpzlkxdwh) = vzgzbkkmhq osrjumhjlv (qnojcydfdl, ofgixvfgam - zybajszciz) View more	-	29 May 2019
				Placebo (Placebo)	mlntsourwi(inpzlkxdwh) = cefemlhzje osrjumhjlv (qnojcydfdl, yvbiuriouh - goouxjfpcr) View more
EASD2018	Not Applicable	-	8	Glutamine 30g	atkfyescws(neypigpump) = byaeqxgcof daitbvpcbu (cqxzueqspw ) View more	Positive	04 Oct 2018
				glutamine (Low-nutrient drink)	atkfyescws(neypigpump) = jfyzzzrxea daitbvpcbu (cqxzueqspw ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis